Welcome to our dedicated page for Mirion Technologies news (Ticker: MIR), a resource for investors and traders seeking the latest updates and insights on Mirion Technologies stock.
Overview
Mirion Technologies Inc is a globally recognized provider of advanced nuclear safety, radiation detection, and medical diagnostics solutions. For over 50 years, the company has delivered precision products and services designed to safely harness and manage ionizing radiation across critical markets. With a strong reputation for protecting people, property, and the environment, Mirion stands as an essential partner in applications where accurate radiation measurement and monitoring are a matter of safety and progress.
Business Segments
Mirion Technologies is uniquely structured through two primary business segments:
- Nuclear & Safety: This segment focuses on radiation safety, measurement, and analysis for the nuclear energy sector, research laboratories, defense, and homeland security. It underpins industries that rely on secure operations and rigorous safety protocols in environments exposed to nuclear and radiological hazards.
- Medical: Dedicated to enhancing the quality and safety of cancer care and medical diagnostics, this division supports critical applications in healthcare. The products and services developed here directly improve practitioner safety and patient care through advanced radiation processing and management technologies.
Products and Services
Mirion provides a comprehensive portfolio that includes radiation detection instruments, monitoring systems, and sophisticated analytical software. The company’s solutions are designed not only to detect ionizing radiation but also to analyze and monitor its effects in real time. These capabilities are vital for ensuring operational safety in a wide array of environments, from medical facilities to research laboratories and industrial sites.
Global Presence and Industry Impact
With facilities strategically located across Europe, Asia, and North America, Mirion Technologies has established a robust global footprint. Its headquarters in the San Francisco Bay Area serve as a hub for innovation and operational excellence. The company’s longevity and consistent performance in high-stakes industries underscore its importance as an industry stalwart, trusted by customers worldwide.
Market Position and Competitive Landscape
Mirion occupies a critical niche within the nuclear and medical safety sectors. Its sophisticated product line and strategic segmentation allow it to address very specific industry needs. In a competitive landscape populated with companies offering radiation measurement and safety solutions, Mirion differentiates itself through decades of technical expertise, global reach, and a steadfast commitment to quality. The company’s balanced approach to innovation and safety ensures it remains an essential component in the ecosystem of technologies that mitigate radiological risks.
Expertise and Technological Innovation
Mirion Technologies places a high premium on technological rigor and expert craftsmanship. Its solutions are developed through extensive research and are continuously refined to meet the strictest safety standards. The depth of its engineering expertise is evident in every aspect of its product offerings, supporting industries that depend on reliable, accurate, and timely radiation measurements.
Conclusion
Overall, Mirion Technologies Inc stands as a profound example of operational excellence within the critical fields of radiation safety and medical diagnostics. Its dual-segment strategy caters to distinct but equally important markets, reinforcing the company’s longstanding commitment to protecting lives and advancing technology. For stakeholders seeking a clear understanding of the company, Mirion represents a well-balanced blend of history, innovation, and technical precision.
Mirion Technologies (NYSE: MIR) has launched version 1.2 of its Apex-Guard gamma spectroscopy software, enhancing quality control in radiopharmaceutical production. The updated software introduces a patent-pending algorithm for Radionuclidic purity measurements, supporting compliance with FDA regulations.
The release comes amid rapid expansion in the radiopharmaceutical sector, with over 100 drugs in Phase I or further clinical development. The software builds upon Mirion's Genie™ and Apex-Gamma™ platforms, offering advanced controls, security, and audit features. It integrates with BioTrax QMS®, an electronic quality management system from ec2 Software, a Mirion Medical Company.
This enhancement aims to streamline quality management processes and ensure compliance in radioisotope production, particularly important for cancer care applications.
Mirion Technologies (NYSE: MIR) has secured contracts to provide critical systems for TerraPower's Natrium Reactor Demonstration Project in Wyoming, the first commercial advanced nuclear power plant in the U.S. The project, a public-private partnership between TerraPower and the U.S. Department of Energy, will implement Natrium technology combining a sodium-cooled fast reactor with molten salt energy storage.
Mirion will deliver two key systems:
- Radiation Monitoring System (RMS) featuring area, effluent, and process radiation monitors for continuous plant safety monitoring
- Nuclear Instrumentation System (XIS) for detecting reactor power levels
The contracts position Mirion to support innovative nuclear technologies, including small and advanced modular reactors, contributing to meeting modern energy demands with safe, sustainable nuclear power.
Mirion Technologies (NYSE: MIR), a leading provider of advanced radiation safety solutions, has announced its membership in two major nuclear industry organizations. The company has joined the Nuclear Energy Institute (NEI) and enhanced its partnership with the American Nuclear Society (ANS) as a Trustees of Nuclear partner.
Through NEI membership, Mirion will participate in policy discussions shaping the nuclear industry and advocate for nuclear energy growth policies. As an ANS Trustee of Nuclear, the company will serve on its leadership council. CEO Thomas Logan emphasized Mirion's unique position across the nuclear landscape and its commitment to advancing the industry through these strategic partnerships.
Mirion Technologies (NYSE: MIR) has announced its participation in the 46th Annual Raymond James Institutional Investor Conference. The company's leadership team, including CEO Thomas Logan and CFO Brian Schopfer, will deliver a presentation scheduled for Wednesday, March 5, 2025, at 9:15 a.m. ET.
The presentation will be accessible through a live webcast on Mirion's Investor Relations Page under the 'Events and Presentations' section. An archived version of the webcast will also be made available at the same location for those unable to attend the live session.
Mirion Technologies (NYSE: MIR) has announced its participation in Citi's 2025 Global Industrial Tech and Mobility Conference in Miami, FL. The company's leadership, including CEO Thomas Logan and CFO Brian Schopfer, will deliver a presentation scheduled for Wednesday, February 19, 2025, at 2:40 PM ET.
Investors and interested parties can access the live webcast through Mirion's Investor Relations Page under the 'Events and Presentations' section. An archived version of the presentation will also be made available at the same location for those unable to attend the live event.
Mirion (NYSE: MIR) reported strong financial results for Q4 and full year 2024, with significant improvements across key metrics. Q4 revenues increased 10.4% to $254.3 million, while GAAP net income reached $15.9 million, marking a 210% improvement from the previous year's loss. The company achieved $69.6 million in Adjusted EBITDA, up 14.1% year-over-year.
For 2025, Mirion reaffirmed its guidance, projecting total revenue growth of 4.0-6.0% and organic revenue growth of 5.5-7.5%. The company expects Adjusted EBITDA between $215-230 million and introduced Adjusted EPS guidance of $0.45-0.50 per share. Notably, Mirion entered 2025 with approximately half of expected revenue already in backlog and is advancing discussions on $300-400 million in potential large orders.
Mirion Technologies (NYSE: MIR) has announced its schedule for the release of fourth quarter and full year 2024 financial results. The company will publish its results after market close on Tuesday, February 11, 2025, followed by a conference call on Wednesday, February 12, 2025, at 11:00 am ET.
Investors and interested parties can access the earnings call by dialing 1-877-407-9208 (US) or 1-201-493-6784 (International). A live webcast will be available on the company's investor relations website. A replay of the call will be accessible until February 26, 2025, using access code 13751221, and will also be archived on Mirion's investor website.
Mirion Technologies (NYSE: MIR) is hosting an Investor Day at the New York Stock Exchange to present its updated strategic and financial outlook. The company projects revenue of $1.1 billion by 2028, with 6-8% organic revenue growth, and targets an adjusted EBITDA margin of 30%. For 2025, Mirion forecasts organic revenue growth of 5.5-7.5% and adjusted EBITDA of $215-230 million. The company highlights its position in nuclear power and cancer care markets, announcing an anti-dilutive share repurchase program and updated capital allocation strategy. Management will discuss market opportunities in nuclear power growth, cancer care dynamics, and operational excellence initiatives.
Mirion Technologies (NYSE: MIR) has announced its participation in the Goldman Sachs' Industrials and Materials Conference in New York. CEO Thomas Logan and CFO Brian Schopfer will deliver a presentation on Thursday, December 5, 2024, at 10:40 AM ET. The event will be accessible via live webcast on Mirion's Investor Relations Page under the 'Events and Presentations' section, with an archived version available afterward.
Mirion (NYSE: MIR) reported Q3 2024 results with revenues increasing 8.2% to $206.8 million. Despite a net loss of $14.0 million, the company showed improved operational performance with Adjusted EBITDA rising 17.8% to $45.7 million and margin expanding to 22.1%. Adjusted EPS reached $0.08, up from $0.05 year-over-year.
The company updated its FY2024 guidance, raising revenue growth expectations to 6-7% and organic growth to 5-6%. Mirion maintains its Adjusted EBITDA target of $195-205 million and Adjusted EPS of $0.37-0.42, while tightening its adjusted free cash flow range to $65-75 million.
FAQ
What is the current stock price of Mirion Technologies (MIR)?
What is the market cap of Mirion Technologies (MIR)?
What does Mirion Technologies Inc specialize in?
How is the company structured?
Which industries does Mirion serve?
What types of products and services does Mirion offer?
How long has Mirion been in operation?
What is the global presence of Mirion Technologies?
How does Mirion differentiate itself from competitors?
What role does Mirion play in the medical sector?
